An Active Surveillance Study to Monitor the Safety of Abrocitinib Among Real-World Patients with Atopic Dermatitis (AD) in the European Union (EU) First published 30/10/2024 Last updated 07/01/2025 EU PAS number:EUPAS1000000282 Study Ongoing